Fly News Breaks for January 9, 2020
Jan 9, 2020 | 06:17 EDT
UBS analyst Navin Jacob upgraded Madrigal Pharmaceuticals to Buy from Neutral with a price target of $127, up from $125. The analyst sees an attractive risk/reward on the shares saying we're now one year closer to a Phase 3 readout and competition concerns are largely priced in. The stock has pulled back in the last month driven in part by a top holder selling a portion of its stake, which creates a "unique opportunity," Jacob tells investors in a research note.
News For MDGL From the Last 2 Days
There are no results for your query MDGL